General features of patients with anti-MDA5-positive CADM with and without anti-Ro52 antibodies
| Characteristics . | Total (N = 83) . | Anti-Ro52 antibody positive (N = 62) . | Anti-Ro52 antibody negative (N = 21) . | P-value . |
|---|---|---|---|---|
| Gottron papule/sign, % (n/N) | 92.8 (77/83) | 93.5 (58/62) | 90.5 (19/21) | 0.640 |
| Heliotrope, % (n/N) | 57.8 (48/83) | 56.5 (35/62) | 61.9 (13/21) | 0.662 |
| Cutaneous ulceration, % (n/N) | 21.7 (18/83) | 27.4 (17/62) | 4.8 (1/21) | 0.033 |
| Periungual erythema, % (n/N) | 24.1 (20/83) | 24.2 (15/62) | 23.8 (5/21) | 0.972 |
| Articular symptom, % (n/N) | 33.7 (28/83) | 32.3 (20/62) | 38.1% (8/21) | 0.625 |
| Hoarseness, % (n/N) | 7.2 (6/83) | 9.7 (6/62) | 0 | 0.330 |
| Sore throat, % (n/N) | 3.6 (3/83) | 4.8 (3/62) | 0 | 0.568 |
| HRCT score, % (n/N) | 138.4 (32.7) | 141.2 (34.6) | 130.1 (25.1) | 0.179 |
| RP-ILD, % (n/N) | 47.0 (39/83) | 54.8 (34/62) | 23.8 (5/21) | 0.014 |
| Exposure to high-dose glucocorticoid (>80 mg), % (n/N) | 30.1 (25/83) | 35.5 (22/62) | 14.3 (3/21) | 0.067 |
| Immunosuppressants, % (n/N) | ||||
| Ciclosporin | 25.3 (21/83) | 25.8 (16/62) | 23.8 (5/21) | 0.856 |
| Tacrolimus | 31.3 (26/83) | 33.8 (21/62) | 23.8 (5/21) | 0.390 |
| Cyclophosphamide | 10.8 (9/83) | 11.3 (7/62) | 9.5 (2/21) | 1.000 |
| Mycophenolate mofetil | 8.4 (7/83) | 6.5 (4/62) | 14.2 (3/21) | 0.362 |
| Azathioprine | 6.0 (5/83) | 8.1 (5/62) | 0 | 0.323 |
| Exposure to pirfenidone, % (n/N) | 14.5 (12/83) | 12.9 (8/62) | 19.0 (4/21) | 0.488 |
| Characteristics . | Total (N = 83) . | Anti-Ro52 antibody positive (N = 62) . | Anti-Ro52 antibody negative (N = 21) . | P-value . |
|---|---|---|---|---|
| Gottron papule/sign, % (n/N) | 92.8 (77/83) | 93.5 (58/62) | 90.5 (19/21) | 0.640 |
| Heliotrope, % (n/N) | 57.8 (48/83) | 56.5 (35/62) | 61.9 (13/21) | 0.662 |
| Cutaneous ulceration, % (n/N) | 21.7 (18/83) | 27.4 (17/62) | 4.8 (1/21) | 0.033 |
| Periungual erythema, % (n/N) | 24.1 (20/83) | 24.2 (15/62) | 23.8 (5/21) | 0.972 |
| Articular symptom, % (n/N) | 33.7 (28/83) | 32.3 (20/62) | 38.1% (8/21) | 0.625 |
| Hoarseness, % (n/N) | 7.2 (6/83) | 9.7 (6/62) | 0 | 0.330 |
| Sore throat, % (n/N) | 3.6 (3/83) | 4.8 (3/62) | 0 | 0.568 |
| HRCT score, % (n/N) | 138.4 (32.7) | 141.2 (34.6) | 130.1 (25.1) | 0.179 |
| RP-ILD, % (n/N) | 47.0 (39/83) | 54.8 (34/62) | 23.8 (5/21) | 0.014 |
| Exposure to high-dose glucocorticoid (>80 mg), % (n/N) | 30.1 (25/83) | 35.5 (22/62) | 14.3 (3/21) | 0.067 |
| Immunosuppressants, % (n/N) | ||||
| Ciclosporin | 25.3 (21/83) | 25.8 (16/62) | 23.8 (5/21) | 0.856 |
| Tacrolimus | 31.3 (26/83) | 33.8 (21/62) | 23.8 (5/21) | 0.390 |
| Cyclophosphamide | 10.8 (9/83) | 11.3 (7/62) | 9.5 (2/21) | 1.000 |
| Mycophenolate mofetil | 8.4 (7/83) | 6.5 (4/62) | 14.2 (3/21) | 0.362 |
| Azathioprine | 6.0 (5/83) | 8.1 (5/62) | 0 | 0.323 |
| Exposure to pirfenidone, % (n/N) | 14.5 (12/83) | 12.9 (8/62) | 19.0 (4/21) | 0.488 |
The chi-squared or Fisher’s exact test was used to compare categorical variables, while continuous data were compared employing the Student’s t-test or Mann–Whitney U-test.
General features of patients with anti-MDA5-positive CADM with and without anti-Ro52 antibodies
| Characteristics . | Total (N = 83) . | Anti-Ro52 antibody positive (N = 62) . | Anti-Ro52 antibody negative (N = 21) . | P-value . |
|---|---|---|---|---|
| Gottron papule/sign, % (n/N) | 92.8 (77/83) | 93.5 (58/62) | 90.5 (19/21) | 0.640 |
| Heliotrope, % (n/N) | 57.8 (48/83) | 56.5 (35/62) | 61.9 (13/21) | 0.662 |
| Cutaneous ulceration, % (n/N) | 21.7 (18/83) | 27.4 (17/62) | 4.8 (1/21) | 0.033 |
| Periungual erythema, % (n/N) | 24.1 (20/83) | 24.2 (15/62) | 23.8 (5/21) | 0.972 |
| Articular symptom, % (n/N) | 33.7 (28/83) | 32.3 (20/62) | 38.1% (8/21) | 0.625 |
| Hoarseness, % (n/N) | 7.2 (6/83) | 9.7 (6/62) | 0 | 0.330 |
| Sore throat, % (n/N) | 3.6 (3/83) | 4.8 (3/62) | 0 | 0.568 |
| HRCT score, % (n/N) | 138.4 (32.7) | 141.2 (34.6) | 130.1 (25.1) | 0.179 |
| RP-ILD, % (n/N) | 47.0 (39/83) | 54.8 (34/62) | 23.8 (5/21) | 0.014 |
| Exposure to high-dose glucocorticoid (>80 mg), % (n/N) | 30.1 (25/83) | 35.5 (22/62) | 14.3 (3/21) | 0.067 |
| Immunosuppressants, % (n/N) | ||||
| Ciclosporin | 25.3 (21/83) | 25.8 (16/62) | 23.8 (5/21) | 0.856 |
| Tacrolimus | 31.3 (26/83) | 33.8 (21/62) | 23.8 (5/21) | 0.390 |
| Cyclophosphamide | 10.8 (9/83) | 11.3 (7/62) | 9.5 (2/21) | 1.000 |
| Mycophenolate mofetil | 8.4 (7/83) | 6.5 (4/62) | 14.2 (3/21) | 0.362 |
| Azathioprine | 6.0 (5/83) | 8.1 (5/62) | 0 | 0.323 |
| Exposure to pirfenidone, % (n/N) | 14.5 (12/83) | 12.9 (8/62) | 19.0 (4/21) | 0.488 |
| Characteristics . | Total (N = 83) . | Anti-Ro52 antibody positive (N = 62) . | Anti-Ro52 antibody negative (N = 21) . | P-value . |
|---|---|---|---|---|
| Gottron papule/sign, % (n/N) | 92.8 (77/83) | 93.5 (58/62) | 90.5 (19/21) | 0.640 |
| Heliotrope, % (n/N) | 57.8 (48/83) | 56.5 (35/62) | 61.9 (13/21) | 0.662 |
| Cutaneous ulceration, % (n/N) | 21.7 (18/83) | 27.4 (17/62) | 4.8 (1/21) | 0.033 |
| Periungual erythema, % (n/N) | 24.1 (20/83) | 24.2 (15/62) | 23.8 (5/21) | 0.972 |
| Articular symptom, % (n/N) | 33.7 (28/83) | 32.3 (20/62) | 38.1% (8/21) | 0.625 |
| Hoarseness, % (n/N) | 7.2 (6/83) | 9.7 (6/62) | 0 | 0.330 |
| Sore throat, % (n/N) | 3.6 (3/83) | 4.8 (3/62) | 0 | 0.568 |
| HRCT score, % (n/N) | 138.4 (32.7) | 141.2 (34.6) | 130.1 (25.1) | 0.179 |
| RP-ILD, % (n/N) | 47.0 (39/83) | 54.8 (34/62) | 23.8 (5/21) | 0.014 |
| Exposure to high-dose glucocorticoid (>80 mg), % (n/N) | 30.1 (25/83) | 35.5 (22/62) | 14.3 (3/21) | 0.067 |
| Immunosuppressants, % (n/N) | ||||
| Ciclosporin | 25.3 (21/83) | 25.8 (16/62) | 23.8 (5/21) | 0.856 |
| Tacrolimus | 31.3 (26/83) | 33.8 (21/62) | 23.8 (5/21) | 0.390 |
| Cyclophosphamide | 10.8 (9/83) | 11.3 (7/62) | 9.5 (2/21) | 1.000 |
| Mycophenolate mofetil | 8.4 (7/83) | 6.5 (4/62) | 14.2 (3/21) | 0.362 |
| Azathioprine | 6.0 (5/83) | 8.1 (5/62) | 0 | 0.323 |
| Exposure to pirfenidone, % (n/N) | 14.5 (12/83) | 12.9 (8/62) | 19.0 (4/21) | 0.488 |
The chi-squared or Fisher’s exact test was used to compare categorical variables, while continuous data were compared employing the Student’s t-test or Mann–Whitney U-test.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
